Weight Management
Research peptides studied for their roles in GLP-1 receptor agonism, appetite regulation, incretin signaling, and metabolic rate modulation in preclinical and clinical weight management models.
The weight loss revolution — the same molecule in Ozempic that helps millions lose 15-20% of body weight by silencing food cravings and resetting appetite at the brain level.
- Lose 15-20% of body weight without willpower or starvation
- Completely eliminates food noise and constant cravings
Extended semaglutide supply for serious weight loss — 6mg for longer protocols. The compound behind the biggest weight loss transformation in medical history.
- Double-dose for sustained weight loss programs
- 15-20% body weight reduction documented in trials
Retatrutide 12mg
12mgThe most powerful weight loss compound ever studied — triple-receptor agonist that achieved 24% body weight loss in trials, outperforming semaglutide by hitting THREE metabolic pathways.
- Triple-action weight loss — targets GLP-1, GIP, AND glucagon receptors
- 24% body weight loss in trials — MORE than semaglutide
Entry dose of the most powerful weight loss peptide in existence — starter Retatrutide for those beginning the triple-agonist protocol that's making Ozempic look like last gen.
- Triple-agonist technology — next generation beyond Ozempic
- Starter dose for the most effective weight loss peptide available
AOD 9604
5mgThe fat-burning fragment of growth hormone — targets and destroys stubborn body fat (especially belly fat) without touching muscle, blood sugar, or hormone levels.
- Burns fat without affecting blood sugar or growth hormone levels
- Targets stubborn belly fat specifically
Cagrilintide
5mgThe semaglutide amplifier — a long-acting amylin that pairs with GLP-1 drugs to supercharge weight loss. Part of the CagriSema combination that's the next breakthrough.
- Long-acting amylin analog for appetite suppression
- Pairs with semaglutide for enhanced weight loss (CagriSema)
SemaCagri Tre Blend
10mg/10mgThe nuclear option for weight loss — three of the most powerful metabolic compounds combined into one protocol. Hits every appetite and fat-burning pathway known to science.
- Triple-compound weight loss protocol in one preparation
- Combines semaglutide + cagrilintide + retatrutide mechanisms
Mazdutide
5mgDual-action fat burner — hits both GLP-1 and glucagon receptors for aggressive fat loss, with special effectiveness against dangerous liver fat and NAFLD.
- Dual GLP-1/glucagon agonist for aggressive fat loss
- Particularly effective against liver fat (NAFLD)
Tesofensine 500mcg
500mcg × 60 CapsulesThe appetite killer that boosts your mood — blocks reuptake of three feel-good neurotransmitters, eliminating hunger while giving you energy and focus. Oral, no injection.
- Twice as effective as current weight loss drugs in clinical trials
- Works through dopamine/serotonin/norepinephrine — triple reuptake
Setmelanotide
15mgMelanocortin appetite control — targets the brain's MC4R hunger circuits (the same system PT-141 uses for arousal), reducing food obsession while potentially boosting libido.
- FDA-approved for genetic obesity (MC4R pathway)
- Reduces hunger in leptin-resistant individuals
About Weight Management Research
The Weight Management collection features the most actively researched compounds in modern obesity science. Semaglutide, a GLP-1 receptor agonist, has generated unprecedented clinical interest for its effects on appetite suppression and glycemic control. Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. AOD 9604 is a modified fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of full-length hGH. Cagrilintide is a long-acting amylin analog under investigation for synergistic weight reduction. Tesofensine is a triple monoamine reuptake inhibitor studied for central appetite suppression. This category serves researchers at the forefront of metabolic disease and obesity pharmacology.